SCHEMBL8912902

SCHEMBL8912902

CC1(C)Oc2cccc(C(=O)O)c2O1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
ALOX5 P09917 1/20 0.41
ALOX15 P16050 2/20 0.40
MYC P01106 1/20 0.40
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
CYP2C9 P11712 1/20 0.38
RAB9A P51151 1/20 0.36
TSHR P16473 2/20 0.36
NR4A1 P22736 1/20 0.36
NR4A2 P43354 1/20 0.36
NR4A3 Q92570 1/20 0.36
NPC1 O15118 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
HMGB1 P09429 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14578221 0.81 ALDH1A1 (0.55) ALDH1A1ALOX5ALOX15MYCKDM4E
SCHEMBL8900720 0.81 ALOX5 (0.39) ALDH1A1ALOX5ALOX15MYCKDM4E
SCHEMBL7896462 0.81 CNR1 (0.42) ALDH1A1ALOX5ALOX15MYCKDM4E
SCHEMBL26290447 0.77 SELL (0.41) ALDH1A1ALOX15KDM4EHPGDHSD17B10
Hydrochloric Acid SCHEMBL9235440 0.77 ALOX5 (0.41) ALDH1A1ALOX5ALOX15MYCKDM4E
SCHEMBL10520286 0.77 ALDH1A1 (0.40) ALDH1A1MYCKDM4EHPGDHSD17B10
SCHEMBL4860502 0.76 ALOX5 (0.43) ALDH1A1ALOX5ALOX15MYCKDM4E
SCHEMBL31474116 0.76 ALDH1A1 (0.39) ALDH1A1KDM4EHPGDCYP2C9RAB9A
SCHEMBL5846456 0.74 TSHR (0.43) ALDH1A1KDM4EHPGDCYP2C9RAB9A
SCHEMBL15625037 0.73 PKM (0.39) ALDH1A1ALOX15KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12044968-B2 Protective film-forming composition having acetal structure and amide structure NISSAN CHEMICAL CORPORATION (JP) 2024-07-23 US disclosed
US-12044968-B2 Protective film-forming composition having acetal structure and amide structure NISSAN CHEMICAL CORPORATION (JP) 2024-07-23 US disclosed
US-11834456-B2 11,13-modified saxitoxins for the treatment of pain SITEONE THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
US-11834456-B2 11,13-modified saxitoxins for the treatment of pain SITEONE THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
EP-3860714-B1 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS INC (US) 2023-09-06 EP disclosed
US-11236097-B2 11,13-modified saxitoxins for the treatment of pain SITEONE THERAPEUTICS, INC. (US) 2022-02-01 US disclosed
US-20220026806-A1 PROTECTIVE FILM-FORMING COMPOSITION HAVING ACETAL STRUCTURE AND AMIDE STRUCTURE NISSAN CHEMICAL CORPORATION (JP) 2022-01-27 US disclosed
US-20220009938-A1 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS, INC. 2022-01-13 US disclosed
EP-3601290-B1 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS INC (US) 2021-11-24 EP disclosed
US-20200409260-A1 PROTECTIVE FILM FORMING COMPOSITION HAVING AN ACETAL STRUCTURE NISSAN CHEMICAL CORPORATION (JP) 2020-12-31 US disclosed
WO-2020072835-A1 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS, INC. (US) 2020-04-09 WO disclosed
US-20200102318-A1 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2020-04-02 US disclosed
US-20200102317-A1 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS, INC. 2020-04-02 US disclosed
US-5686633-A PHOTOSTABILIZERS CIBA SPECIALTY CHEMICALS CORPORATION (US) 1997-11-11 US disclosed
US-5098477-A Aromatic ether derivatives as light stabilizers for organic materials CIBA-GEIGY CORPORATION (US) 1992-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236097-B2 11,13-modified saxitoxins for the treatment of pain SCN11A, SCN10A, CACNA1A ALDH1A1 4050/4885ALOX5 2930/4885ALOX15 2983/4885
US-11834456-B2 11,13-modified saxitoxins for the treatment of pain SCN11A, SCN10A, CACNA1A ALDH1A1 4050/4885ALOX5 2930/4885ALOX15 2983/4885
US-20200102318-A1 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN SCN11A, SCN10A, CACNA1A ALDH1A1 4050/4885ALOX5 2930/4885ALOX15 2983/4885
US-20200102317-A1 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN SCN11A, SCN10A, SCN3A ALDH1A1 3422/4885ALOX5 2206/4885ALOX15 1730/4885
US-20220009938-A1 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN SCN11A, SCN10A, SCN3A ALDH1A1 3205/4885ALOX5 2104/4885ALOX15 1698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.